Polymerase News and Research

RSS

Guidelines for accurate amplicon-based sequencing of SARS-CoV-2

A new study describes much-needed guidelines for reliable viral sequencing, validated in a large group of clinical samples.

3 Dec 2020

New lab-on-a-chip can process and present results rapidly

The chip, developed at Imperial College London and known as TriSilix, is a 'micro laboratory' which performs a miniature version of the polymerase chain reaction (PCR) on the spot. PCR is the gold-standard test for detecting viruses and bacteria in biological samples such as bodily fluids, faeces, or environmental samples.

2 Dec 2020

Researchers evaluate the most appropriate test for COVID-19

Until a vaccine is available, curbing the coronavirus pandemic relies heavily on how quickly a potentially exposed individual can be tested and quarantined.

2 Dec 2020

Research suggests plant flavonols could serve as effective antivirals for SARS-CoV-2

Researchers in Algeria have reviewed some of the evidence suggesting that flavonols commonly found in many plants and vegetables could be used as a therapeutic approach to coronavirus disease 2019 (COVID-19).

1 Dec 2020

How COVID-19 highlights the uncertainty of medical testing

Dr. Jacqueline Chu considered the man with a negative coronavirus test on the other end of the phone, and knew, her heart dropping, that the test result was not enough to clear him for work.

1 Dec 2020

Chinese woman still sheds SARS-CoV-2 over four months post-infection

A new study by Chinese scientists explore an unusual case of extended viral shedding in a 68-year-old woman up to four months post-infection.

1 Dec 2020

Severe COVID-19 can produce high long-term neutralizing antibodies, study finds

A new study published by a team of scientists in Spain indicates that neutralizing immunity can last for up to 8 months, despite a steep drop in antibody titer over this time.

30 Nov 2020

Steam inhalation therapy found to inactivate SARS-CoV-2 virions

Researchers have published a study on the efficacy of steam inhalations as another possible treatment to help mitigate SARS-CoV-2 infection.

30 Nov 2020

Resveratrol shows potential as SARS-CoV-2 antiviral, study finds

A recent study reveals that resveratrol, a phenolic compound produced by spermatophytes, can inhibit the viral replication SARS-CoV-2.

27 Nov 2020

SARS-CoV-2 launches multipronged attack against host cell protein synthesis, study finds

An interesting new study throws a flood of light on how SARS-CoV-2 accomplishes its mission to infect and replicate within host cells while evading the host immune response.

27 Nov 2020

Monoclonal antibody HB27 shows potent neutralizing activity against SARS-CoV-2

A new study reports a very promising anti-SARS-CoV-2 monoclonal antibody, HB27, that appears to have two distinct mechanisms of action inhibiting the virus-host cell interaction and subsequent infection.

27 Nov 2020

$Multiple fractionation approach for measuring cancer biomarker enrichment in exosomes$

Multiple fractionation approach for measuring cancer biomarker enrichment in exosomes

Postnova Analytics reports that researchers from the University of Utah have used a novel combination of Asymmetrical Flow Field-Flow Fractionation and Centrifugal Field-Flow Fractionation to measure cancer biomarker enrichment in exosomes.

From Postnova Analytics 27 Nov 2020

Body mass index and severe COVID-19

French researchers led by first author Abdallah Al-Salameh from the Department of Endocrinology, Diabetes Mellitus and Nutrition, Amiens University Hospital, Amiens, France, have published findings of their study titled, “The association between body mass index class and coronavirus disease 2019 outcomes,” in the latest issue of the International Journal of Obesity.

26 Nov 2020

COVID-19 may trigger recurrent Guillain–Barré Syndrome episodes, a case study shows

A team of researchers at the Robert Wood Johnson Medical School, Rutgers University, USA, have investigated a case wherein a man experienced recurrent episodes of Guillain–Barré Syndrome after being infected with SARS-CoV-2.

26 Nov 2020

Antihypertensive drugs may reduce COVID-19 mortality in at-risk patients

A new multicenter study that recently appeared on the medRxiv* preprint server in November 2020 has found a lower or equal risk of fatal COVID-19 in hypertensive patients, depending on the type of medication they are on.

26 Nov 2020

Phycobilins found to inhibit SARS-CoV-2 enzymes in vitro

Researchers have released an interesting new study that describes the broad-spectrum of antiviral activity that phycobilins can have. Phycobilins, which are bioactive plant compounds, were found to inhibit two coronavirus enzymes.

26 Nov 2020

Specific SARS-CoV-2 genomic variations are associated with higher COVID-19 deaths

A team of scientists from South Korea and the United States has conducted an interesting study to investigate whether mutations in the genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can affect the severity of coronavirus disease 2019 (COVID-19). The study findings reveal that mutations in the viral spike protein and RNA polymerase complex can increase the risk of COVID-19 mortality.

25 Nov 2020

Why employers find it so hard to test for COVID

Brandon Hudgins works the main floor at Fleet Feet, a running-shoe store chain, for more than 30 hours a week. He chats with customers, measuring their feet and dashing in and out of the storage area to locate right-sized shoes. Sometimes, clients drag their masks down while speaking. Others refuse to wear masks at all.

25 Nov 2020

SARS-CoV-2 spike protein antibodies can persist up to 200 days after symptom onset

Researchers report SARS-CoV-2 antibodies to the spike protein (S protein) can persist 200 days after symptom onset, but that antibodies to the nucleoprotein (N protein) can reduce much more rapidly.

25 Nov 2020

Robust antibody response to SARS-CoV-2 can persist for eight months, study finds

A study conducted by researchers based in Italy suggests that SARS-CoV-2 induces durable and strong immunity in patients who had moderate to severe COVID-19.

25 Nov 2020